|
NCT identifier | Status | Location | Study type | Condition or disease | Intervention and phase | Primary outcome | Estimated completion date |
|
NCT04409925 | Not yet recruiting | Canada | Nonrandomized pilot study | COVID-19 | Dornase Alfa Phase: 1 | (1) Rate of all adverse events | January 2021 |
NCT04359654 | Not yet recruiting | United Kingdom | Randomized clinical trial | COVID-19 Hypoxia | Drug: Dornase Alfa Phase: 2 | (1) Change in inflammation (C-reactive protein) | November 2020 |
NCT04445285 | Recruiting | United States | Randomized clinical trial | COVID-19 | Dornase Alfa Phase: 2 | (1) All-cause mortality (2) Systemic therapeutic response | February 2021 |
NCT04432987 | Recruiting | Turkey | Randomized clinical trial | COVID-19 | Dornase Alfa Phase: 2 | (1) Clinical improvement and inflammatory markers in blood (2) Intubation or extubation | September 2020 |
NCT04402944 | Not yet recruiting | United States | Randomized clinical trial | COVID-19 | Dornase Alfa Phase: 2 | (1) Ventilator-free days | December 2021 |
NCT04322565 | Recruiting | Italy | Randomized clinical trial | COVID-19 Pneumonia | Colchicine Phase: 2 | (1) Clinical improvement (2) Hospital discharge | December 2020 |
NCT04326790 | Recruiting | Greece | Randomized clinical trial | COVID-19 | Colchicine Phase: 2 | (1) Time to clinical deterioration (2) Concentration of cardiac troponin | September 2020 |
NCT04402970 | Recruiting | United States | Nonrandomized clinical trial | COVID-19 ARDS | Dornase Alfa Phase: 3 | (1) Improvement in partial pressure of O2 to fraction of inspired O2 ratio | May 2022 |
NCT04355364 | Recruiting | France | Randomized clinical trial | COVID-19 ARDS | Dornase Alfa Phase: 3 | (1) Occurrence of at least one grade improvement (ARDS scale severity) | August 2020 |
NCT04322682 | Recruiting | United States | Randomized clinical trial | COVID-19 | Colchicine Phase: 3 | (1) Number of participants who die or require hospitalization | December 2020 |
NCT04328480 | Recruiting | Argentina | Randomized clinical trial | COVID-19 | Colchicine Phase: 3 | (1) Number of participants who die (all-cause mortality) | August 2020 |
|